Competitive landscape, page-2

One reason publicly listed speculative companies often attract a lot of hype is because they attract a lot of traders etc who pump the company on social media and stock market forums.

There are likely dozens of competitors who are moving ahead just as quickly, but because they are private companies traders have no incentive to pump the company. If any of these private oncology/oncolytic companies went public, you can bet your bottom dollar traders would swarm the stock market forums and also be posting company X is going to the moon, just like they do for IMU.

It's important to be aware of these privately held companies too.

---------------------
https://www.prnewswire.com/news-releases/kalivir-immunotherapeutics-enters-into-global-exclusive-licensing-agreement-with-roche-for-novel-oncolytic-viruses-301553126.html

KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses
May 23, 2022, 14:16 ET

PITTSBURGH, May 23, 2022 /PRNewswire/ -- KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for the discovery, development and commercialization of novel oncolytic vaccinia viruses derived from KaliVir's oncolytic immunotherapy VETTM platform.

KaliVir will work with Roche to leverage KaliVir's proprietary technology platform based on genetically modified vaccinia virus to discover and develop novel oncolytic virus candidates. KaliVir's VETTM platform can enhance the vaccinia viral backbone with a combination of proprietary genetic modifications to maximize tumor killing and systemic delivery and spread, and can be readily optimized to combine with a wide variety of therapeutic transgenes.